/ Side by side
Semaglutide vs Retatrutide
A neutral, side-by-side look at Semaglutide and Retatrutide: what each one is, its class, half-life, storage, and the public sources behind it. Educational reference only, not medical advice, dosing, or a recommendation to use either compound.
Semaglutide
Ozempic · Wegovy · Rybelsus
Full profile →Retatrutide
Reta · Triple-G · LY3437943
Full profile →| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Category | GLP-1 / Metabolic | GLP-1 / Metabolic |
| Half-life | ~1 week | ~6 days, subcutaneous |
| Common vial | 2, 3, 5, 10 mg | 5, 10, 15, 20, 30 mg |
| Reference | Verified | Verified |
What is Semaglutide?
A GLP-1 receptor agonist, acylated for albumin binding and DPP-4 resistance, studied for glycemic control in type 2 diabetes and for weight management. Its long half-life supports once-weekly administration.
Sources
- FDA label: Ozempic, subcutaneous (NDA 209637)
- FDA label: Wegovy, subcutaneous (NDA 215256)
- FDA label: Rybelsus, oral (NDA 213051)
What is Retatrutide?
An investigational triple receptor agonist (GIP, GLP-1 and glucagon) conjugated to a fatty-diacid for albumin binding, studied in trials for obesity and metabolic disease. Its half-life supports once-weekly administration.
Sources
- Jastreboff et al., NEJM 2023 (phase 2 obesity)
- Nature Medicine 2024 (phase 2a MASLD)
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.